Pacritinib - CAS# 937272-79-2 Size:Solid 10 mg Smiles: C[C@@]12[C@@H]3C(=O)CC[C@]3(CC[C@H]1C)[C@@H](C)[C@H](O)[C@@](C)(C[C@H]2OC(=O)CO)C=C

Smiles: C[C@@]12[C@@H]3C(=O)CC[C@]3(CC[C@H]1C)[C@@H](C)[C@H](O)[C@@](C)(C[C@H]2OC(=O)CO)C=C

Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner

Formula: C13H14N2O

InChi: InChI=1S/C20H13FN4O2/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(8-4-15)25(26)27/h1-12H

InChi: InChI=1S/C33H40N6O/c1-32(2

Pacritinib - CAS# 937272-79-2 Size:Solid 10 mg Smiles: C[C@@]12[C@@H]3C(=O)CC[C@]3(CC[C@H]1C)[C@@H](C)[C@H](O)[C@@](C)(C[C@H]2OC(=O)CO)C=CPacritinib, also known as SB1518, is a n orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK STAT signaling pathway, and so caspase dependent apoptosis. JAK2 is the most common mutated gene in bcr abl negative myeloproliferative disorders; the JAK2V617F gain of